Evelo Biosciences Inc expected to post a loss of 61  cents a share - Earnings Preview

Evelo Biosciences

04/03/2022 13:33

* Evelo Biosciences Inc  EVLO.OQ   EVLO.O  is expected
to show no
change in quarterly revenue when it reports  results on March 7
(estimated). 
    * ​Refinitiv's mean analyst estimate for Evelo Biosciences
Inc is
for a loss of 61 cents per share. For the same quarter last
year, the company reported a loss of 62 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $18.5​, about 83.6% above​ its last closing price
of $3.03. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.55       -0.54      -0.63     Missed  -16.7
 Jun. 30 2021  -0.53       -0.54      -0.53     Beat    2.2
 Mar. 31 2021  -0.51       -0.51      -0.55     Missed  -8.7​
 Dec. 31 2020  -0.59       -0.53      -0.62     Missed  -17.5
 ​​Sep.        -0.50       -0.50      -0.45     Beat    10.4
 30 2020                                                
 Jun. 30 2020  -0.78       -0.78      -0.63     Beat    19.2​
 Mar. 31 2020  -0.72       -0.73      -0.71     Beat    2.9
 Dec. 31 2019  -0.62       -0.61      -0.70     Missed  -14.4
 This summary was machine generated March 4 at 13:32 GMT.  All
figures in US dollars  unless otherwise stated